Apellis Pharmaceuticals Risk Adjusted Performance
| APLS Stock | | | USD 17.20 -0.77 -4.28% |
The Risk Adjusted Performance indicator for Apellis Pharmaceuticals is constructed from normalized market data. All inputs reflect available trading data across supported markets. Some instruments may report limited inputs depending on trading history. Apellis Pharmaceuticals has a market cap of 2.3 B, operating margin of -25.58%, ROE of 7.48%. Use
Trending Equities to view allocation positioning. Allocation details are provided as informational context. This captures an allocation to Apellis Pharmaceuticals. This is part of the broader portfolio composition. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in state.
Our
How to Invest in Apellis Pharmaceuticals guide provides practical guidance on trading Apellis Stock.
Apellis Pharmaceuticals has current Risk Adjusted Performance of
-0.1.
RAP | = | (ER[a] - RFR) * STD[b])/STD[b]RFR |
| = | -0.1 | |
Risk Adjusted Performance Peers Comparison
Risk Adjusted Performance Relative To Other Indicators
Apellis Pharmaceuticals is rated
below average in risk adjusted performance relative to competitors. It is currently under evaluation in maximum drawdown relative to competitors .
Other Technical Indicators